Pfizer to discontinue development programme for PF-07265803 for LMNA-related dilated cardiomyopathy
Decision follows results of interim futility analysis which indicate phase-III REALM-DCM trial unlikely to meet primary endpoint
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.